Clinical Trial

CHaractErizing CFTR Modulated Changes in Sweat Chloride and Their Association With Clinical Outcomes

Study acronym: CHEC-SC
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
This is a multicenter, cross-sectional, cohort study which will collect contemporary sweat chloride (SC) values from approximately 5000 Cystic Fibrosis (CF) patients prescribed and currently receiving commercially approved Cystic Fibrosis transmembrane conductance regulator (CFTR) modulator therapies.
Protocol Amendment History 17 amendments
This ClinicalTrials.gov record has been amended 17 times since 2017-11-20; most recent amendment 2025-10-08.
Status change: Recruiting → Active, Not Recruiting 2024-08-15
Status change: Active, Not Recruiting → Recruiting 2023-11-21
Status change: Recruiting → Active, Not Recruiting 2022-06-16
Status change: Not Yet Recruiting → Recruiting 2018-01-23
Trial Details
NCT Number NCT03350828
Lead Sponsor Nicole Hamblett
Collaborators: Cystic Fibrosis Foundation
Conditions Cystic Fibrosis
Enrollment 5,000 participants
Start Date 2018-01-15
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-10-10